Cefprozil anhydrous, (e)-
As of the edition of 20 October 2026, Cefprozil anhydrous, (e)- is a small molecule: marketed, first approved in 1991 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1991
- Kind
- Small molecule
- Brand name
- Cefzil
- First approved
- 23 December 1991 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Corden Pharma Latina
- Registered trials
- 13, 0 stopped early
- Disease areas
- Infections; Lungs and airways
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 4 | 0 | 0 |
| Phase 1 | 8 | 8 | 0 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Corden Pharma Latina | Acquired holder | 2013 to now |
| Bristol Myers Squibb | Originator | 1991 to 2013 |